home > ict > spring 2021 > top 10 considerations when working with rwe
International Clinical Trials

Top 10 Considerations When Working With RWE

Clinical trials are from Mars, realworld studies are from Venus. For clinical operations professionals, non-traditional real-world observational/ non-interventional studies can seem like they are from an entirely different planet.

However, real-world evidence (RWE) and real-world data (RWD) are becoming indispensable to clinical and commercial development for life science companies that ultimately want to see their innovations positively impact the lives of patients. It’s critical for those who support traditional clinical trials to understand the potentially unfamiliar RWE terrain. So, here are 10 concepts to illuminate the RWE landscape:

1. The Real World: Real Important, but Real Messy

Generally, products are evaluated for regulatory approval under very different conditions than those under which they are used. Controlled clinical trials are essential to our understanding of product safety and efficacy, but real-world use cases reflect a far more heterogeneous scenario.

Real-life conditions are virtually impossible to control from a research perspective. Nor would we want to, as an understanding of the effectiveness, safety, and value of a product under actual practice conditions is a primary goal of real-world research.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

About the Author

Jeff Trotter is Senior Vice President for Worldwide Evidence at Worldwide Clinical Trials. Formerly the President and Co-Founder of Continuum Clinical, Jeff’s healthcare industry career spans 30 years. A leader in the design and implementation of patient registries and observational studies, Jeff founded Ovation Research Group, an internationally known research and consulting firm, and has been in executive management with other clinical research organisations. He is a sought-after speaker who has published over 50 original articles and research papers, including a book for the American Hospital Association, The Quest for Cost-Effectiveness in Healthcare: Achieving Clinical Excellence While Controlling Cost.
Print this page
Send to a friend
Privacy statement
News and Press Releases

Cerevance Establishes Strategic Research Collaboration with Merck for the Discovery of Novel Targets in Alzheimer’s Disease

Boston, MA and Cambridge, UK – AUGUST 9, 2022: Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous system (CNS) diseases, today announced a multi-year strategic research collaboration with Merck, known as MSD outside the United States and Canada, to identify novel targets for Alzheimer’s disease utilizing Cerevance’s proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) technology platform. Cerevance will concurrently out-license one discovery-stage program to Merck as part of the collaboration.
More info >>

White Papers

Planning the Execution of a Viral Clearance Study

Eurofins BioPharma Product Testing

Viral clearance studies are a necessary component of any regulatory submission for clinical trials or commercial product approval for all biopharmaceutical products. These studies are performed to evaluate the capability of the purification process to remove or inactivate viruses that could potentially contaminate the starting material. They are complex studies that require substantial financial and personnel resources, as well as specialized scientific expertise to perform. As such, viral clearance studies are often performed at a qualified contract testing laboratory rather than in-house. When multiple parties are involved in this process, clear communication and a comprehensive understanding of the approach and timeline is critical.
More info >>




©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement